Sign up
Healthed-White-on-Blue
Price-David

Prof David Price

General Practitioner; Founder, Observational and Pragmatic Research Institute, Singapore; Professor, University of Aberdeen, Scotland
Prof David Price is a General Practitioner and Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen (UK). He was awarded Fellow of ERS (FERS) in 2016. He is also a member of the World Health Organization (WHO) Allergic Rhinitis and its Impact on Asthma (ARIA) executive committee, the World Allergy Organization (WAO) Committee on Asthma, and the WAO Education Council.

He is the founder and head of Optimum Patient Care (UK and Australia), a science-based, social enterprise which focuses on disease registries and supporting care in primary and secondary care led by internationally recognised experts in all areas of respiratory medicine.

Prof Price is also the founder of The Observational and Pragmatic Research Institute (Singapore), an independent, research-driven organisation established to cultivate initiatives, provide evidence and drive quality standards within the growing field of real-life, pragmatic and observational research. This dynamic organisation delivers pragmatic clinical trials and real-life database research across multiple geographies, including territories in the United States, Europe and the Asia-Pacific region, such as Singapore, South Korea, Taiwan, The Philippines, New Zealand, Australia, Japan and China.

He is extensively involved in respiratory and allergy research; his areas of special interest are the ‘real-life’ effectiveness and cost-effectiveness of interventions, clinical trial design, adherence, and patient attitudes to their disease. He has authored more than 490 peer-reviewed publications and is responsible for approximately US$50 million in research and clinical development grants. He is currently Editor-in-Chief of the journal Pragmatic and Observational Research and member of the editorial board of several respiratory journals, including The Lancet Respiratory Medicine.

More from this expert

Doctor,Holding,Blue,Asthma,Inhaler,For,Treatment,Copd,Diseases,For

COPD Exacerbation – Inhaled steroids vs Pneumonia Risks – It’s Not Black and White

Respiratory Physician Professor David Price discusses the role of ICS in COPD and outlines how to determine who is likely to benefit from this add-on therapy, who is at increased risk of pneumonia from ICS and what can be done to mitigate this risk.

By Prof David Price
Podcasts iconPodcasts

Discover

Healthed

CPD platform

Upcoming Healthed Webcast

Acute Heart Failure: Practical Steps For GPs After Discharge

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Prof Andrew Sindone AM

Cardiologist; Director of the Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital

Prof Andrew Sindone AM provides the post-discharge essentials: timing the first review, spotting residual congestion, watching renal function and electrolytes, pushing the four pillars to target, and knowing when to refer back.

Register for webcast